Q&A with a Preeclampsia Expert: Dr. Strickland Answers Top Questions

Understanding the signs and symptoms of preeclampsia, combined with routine screening, can save lives.

Central lab capabilities in Japan: Insights from a recent symposium

In this video, Catherine Ohura, VP and general manager at Labcorp laboratories in Japan, alongside Takashi Shibata, site lead for Labcorp Central Laboratories in Japan, provide an overview of Labcorp’s central lab capabilities in Japan. Additionally, Kazuya Kurachi, senior director of global regulatory operations, discusses CDx development in Japan. Discussing the lab’s significant expansions over the years, they detail its steady growth in capabilities. Through a collaboration with BML, the lab is set to grow even further by 2025. The facility’s expanded offerings will include flow cytometry, immunology, and anatomic pathology and histology.

Baseline ctDNA gene alterations as a biomarker of survival after panitumumab and chemotherapy in metastatic colorectal cancer

Novel Diagnostic Markers for Rheumatoid Arthritis Including Anti-CarP (Carbamylated Protein), Anti-Sa (Citrullinated Vimentin) and Anti-CEP1 (Citrullinated Enolase Peptide1) Are Frequently Positive in Diagnostic Profiles

Despite the diagnostic contribution of Anti-CCP 3.1 (cyclic citrullinated peptide) antibody and RF (rheumatoid factor) as classified by the 2010 ACR/EULAR RA criteria, approximately one-third of patients with rheumatoid arthritis (RA) are considered “seronegative.” Novel markers, Anti-CarP Anti-Sa, and Anti-CEP-1 were recently added in order to improve RA diagnosis and characterization. These autoantibodies may predict the development of RA and may be associated with more active disease and higher risk of developing joint erosions.

Therapeutic Drug Monitoring (TDM) of Hydroxychloroquine in Whole Blood: Analysis of Over 10,000 Patient Results Using Lab Developed Liquid Chromatography Tandem Mass Spectrometry

Hydroxychloroquine (HCQ), a mainstay SLE therapy, improves survival and reduces flares. Therapeutic drug monitoring (TDM) may be useful in 1) identifying and improving adherence issues, 2) titrating daily dose to achieve therapeutic benefits associated with whole blood HCQ >1000 ng/mL while 3) minimizing cumulative exposure by keeping levels <2000 ng/mL. Whole blood (WB) is the correct specimen because WB HCQ levels are higher than serum or plasma levels, more stable and reflective of the last month of HCQ ingestion, and are better correlated to efficacy and retinopathy risk.

Correlation of Anti-DFS70 Autoantibodies by ELISA with HEp-2 Cells DFS Pattern by IFA

Anti-DFS70 antibodies are associated with a dense-fine speckled (DFS) pattern by IFA while their clinical associations remain an immunological enigma. This study provides supporting evidence of the significant association between the DFS pattern by IFA and anti-DFS70 antibodies by ELISA and offers a potential algorithm to triage patients to exclude systemic autoimmune rheumatic diseases/ANA-associated rheumatic diseases (SARD/AARD).

Rheumatologic Disorder Diagnostic Testing Patterns: Real World Evidence from a National Laboratory Database

Rheumatologic disorders can take years to diagnose, often requiring a combination of specific symptoms, examination findings and laboratory testing, rather than a single test. Additionally, symptoms presenting in rheumatologic processes are often present in other common conditions, making diagnosis challenging. In this study, we sought to examine patterns of post-ANA testing using real world evidence to inform order guidance opportunities and help advance diagnosis.